Clinical Trial Detail

NCT ID NCT02649764
Title LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Cytarabine + Fludarabine + Prexasertib

Age Groups: adult

No variant requirements are available.